Delta-Fly Pharma, Inc.
Tokyo Stock ExchangeTotal Valuation
Delta-Fly Pharma, Inc. carries a market capitalization of 1.94B, placing it among publicly traded companies globally. Its enterprise value stands at -1.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.94B |
| Enterprise Value | -1.42B |
Share Statistics
Delta-Fly Pharma, Inc. currently has 8.23M shares outstanding.
| Shares Outstanding | 8.23M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Delta-Fly Pharma, Inc. maintains a current ratio of 5.93, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.93 |
| Quick Ratio | 5.87 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -120.07 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 2.50M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Delta-Fly Pharma, Inc.'s stock has declined approximately -76.92308% over the past 52 weeks. The 50-day moving average sits at 188.30, while the 200-day moving average is 374.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | -76.92308% |
| 50-Day Moving Average | 188.30 |
| 200-Day Moving Average | 374.29 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -1.40B, while operating income came in at -1.40B.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.40B |
| Pretax Income | -1.43B |
| Net Income | -1.43B |
| EBITDA | -1.40B |
| EBIT | -1.40B |
| Earnings Per Share (EPS) | -219.34 |
Balance Sheet
Total book value stands at -3.48B, with working capital of 1.19B providing operational flexibility.
| Cash & Cash Equivalents | 1.42B |
| Total Debt | N/A |
| Net Debt | -1.42B |
| Equity (Book Value) | -3.48B |
| Book Value Per Share | -533.83 |
| Working Capital | 1.19B |
Scores
Delta-Fly Pharma, Inc. posts an Altman Z-Score of -9.97, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -9.97 |